Streamlined Geriatric and Oncological Evaluation Based On IC Technology

NCT ID: NCT05720910

Last Updated: 2026-01-15

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 720 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-10-15
• Study Completion Date: 2027-04-30

Brief Summary

The primary objective of GERONTE STUDY is to evaluate the effectiveness of the GERONTE, ICT-based, integrated care pathway to improve patient 6-month quality of life, in France.

Study design is a stepped wedge randomised controlled trial. Clusters will be participating hospitals, comprising eight investigating sites in total (Figure 2).

This is a stepped wedge of cross-over type. Patients included at each "step" are different individuals. The first "step" is a reference measurement where none of the clusters will implement the intervention. The investigating sites will be randomly drawn to determine the order in which they will implement the intervention, by "steps" of two months.

The primary endpoint is the Quality of Life assessed by the EORTC QLQ-C30 (version 3.0) questionnaire at 6 months after GERONTE implementation. It has 3 sub-scores that will be analysed independently, with alpha risk adjustment.

Detailed Description

This is a stepped wedge of cross-over type. Patients included at each "step" are different individuals. The first "step" is a reference measurement where none of the clusters will implement the intervention. The investigating sites will be randomly drawn to determine the order in which they will implement the intervention, by "steps" of two months. A total of 10 patients by step are to be included in each center; these 10 patients must be regularly included along the 2-month period of each step. If 10 patients are already included before the end of the 2 months' step period, the center has to stop the inclusions till the beginning of the subsequent step. If a center, near to the end of a step, is far from reaching of the 10 patients' inclusion, it must increase the speed of its inclusions to be as close as possible of 10 patients included at the end of the step. In each center, patient sample has to be representative of type of cancer managed in the center, along the trial duration. The repartition of cancer types must be homogeneous along the steps and during the trial duration.

All participating investigating sites will have study collaborators in charge of organizing intervention implementation and data collection. The intervention will be prepared prior to the start of the trial, so that each investigating site can implement it as defined by the randomisation. Each center engaged to participate needs to participate till the end of the trial. A center commitment to participate will be requested before each center involvement to avoid center withdrawal after the start of the trial. Quantitative data regarding the myPatientSpace adapted for GERONTE app usage will be collected at each step and in each cluster by study collaborators, from the beginning of GERONTE system implementation. Care outcome data (Quality of life, anxiety, autonomy, additional hospitalisation, mortality...) will be collected by local referents at 3, 6, 9 and 12 months after inclusion in GERONTE. The data necessary to calculate the real cost of the intervention, of its implementation and of resource use data of patient management will be continuously collected during follow-up. GERONTE patient-centered system implementation and usage will be collected by the local referents in each center. Qualitative analysis will be performed in each center at GERONTE system implementation and during follow-up.

Conditions

Breast Cancer; Comorbidities and Coexisting Conditions; Lung Cancer; Colorectal Cancer; Prostate Cancer

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: SUPPORTIVE_CARE
• Blinding Strategy: NONE

Study Groups

GERONTE

The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway;

Group Type: EXPERIMENTAL

GERONTE

Intervention Type: OTHER

The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway

CONTROL ARM

Patients included in the control arm will be managed according to the standard of care.

Group Type: NO_INTERVENTION

No interventions assigned to this group

Interventions

GERONTE

The clinical model behind GERONTE is to regroup all health professionals taking care of a multimorbid patient, into a common care coordination pathway

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Age ≥ 70 years old.

2. New or progressive cancer (breast, lung, colorectal, prostate), histologically proven or strong clinical suspicion, fulfilling the tumor specific criteria.

3. Estimated life expectancy greater than 6 months.

5. Patients must be willing and able to comply with study procedures.

6. Voluntarily signed and dated written informed consents prior to any study specific procedure.

7. QLQ-C30 Quality of Life Questionnaire fully completed at baseline, before inclusion.

8. Patients affiliated with a French social security scheme in accordance with the French law on biomedical research (Article 1121-11 of the French Code of Public health).

9.1. Non-metastatic breast cancer (M0):

• No prior treatment for the current breast cancer.

• All 3 criteria required:

o Clinical staging: cT2-3-4 Nany, or cTany N1-2-3;

• The cancer specialist considers* surgery;
• The cancer specialist considers* radiotherapy and/or chemotherapy. 9.2. Metastatic breast cancer (M1): Both criteria required:

• The cancer specialist considers* chemotherapy or PARP-inhibitors or mTOR-inhibitors / PIK3CA inhibitors; Previous endocrine therapy +/- CDK4/6 inhibitors is allowed;
• The patient received maximum 1 prior line of chemotherapy for metastatic disease.

• 'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.

10.1. Non-metastatic colorectal cancer (M0):

• No prior therapy for the current tumor in the recruiting hospital
• At least one of the 3 criteria required:

o The cancer specialist considers* surgery;

• The cancer specialist considers* radiotherapy;
• The cancer specialist considers* chemotherapy and/or immunotherapy. 10.2. Metastatic colorectal cancer (M1):
• The cancer specialist considers* first or second line systemic therapy and/or radiotherapy (+/- surgery). No previous chemotherapy allowed except adjuvant/perioperative chemotherapy stopped for more than 12 months.

• 'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.

11.1. Non-metastatic lung cancer (M0):

• No prior therapy for the current tumor in the recruiting hospital
• At least one of the 3 criteria required:

• The cancer specialist considers* surgery (patients considered for treatment with percutaneous thermoablation alone are not eligible);
• The cancer specialist considers* radiotherapy (except SBRT);
• The cancer specialist considers* systemic therapy. Possible systemic therapies are chemotherapy and/or immune therapy and/or targeted therapy. Patients only considered* for monotherapy with anti-EGFR TKI or somatostatin analog are not eligible.

11.2. Metastatic lung cancer (M1):

• The cancer specialist considers* first or second line systemic therapy. Possible systemic therapies are chemotherapy and/or immune therapy and/or targeted therapy. Patients only considered* for monotherapy with anti-EGFR TKI or somatostatin analog are not eligible.

*'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.

• First diagnosis M0 prostate cancer (no therapy received yet for prostate cancer): at least one of the 2 criteria required:

o The cancer specialist considers* radiotherapy;

o The cancer specialist considers* hormone therapy (ADT +/- combination Abiraterone and Prednisone).

• Salvage treatment M0 prostate cancer (received prior surgery at least 6 months before):

o The cancer specialist considers* radiotherapy (+/- ADT)

• Non-metastatic castration resistant prostate cancer:

• The cancer specialist considers* treatment intensification (ADT + Enzalutamide or Apalutamide or Darolutamide).

12.2. Metastatic prostate cancer (M1): - The cancer specialist considers* treatment with Abiraterone or Enzalutamide or Apalutamide, or Docetaxel or Cabazitaxel or PARP-inhibitors or Lutetium PSMA.

*'consider' implies that this treatment may be a treatment option for this patient in this particular setting. If at a later point, a different treatment choice is made, the patient remains eligible.

Exclusion Criteria

1. Mental illness/cognitive impairment that limits ability to provide consent or complete trial procedures.

2. Participating to an interventional clinical trial with a non-registered anticancer drug or to another geriatric intervention trial.

3. Patients and caregivers are unable or unwilling to use ICT-devices (tablet,computer, smartphone) or the Internet according to protocol.

4. Patient already included in this study.

• Minimum Eligible Age: 70 Years
• Maximum Eligible Age: 130 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

EUCLID Clinical Trial Platform

OTHER

Sponsor Role: collaborator

University of Bordeaux

OTHER

Sponsor Role: collaborator

Institut Bergonié

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Centre Hospitalier de la Côte Basque

Bayonne, , France

Site Status: RECRUITING

Institut Bergonié

Bordeaux, , France

Site Status: RECRUITING

Centre Hospitalier Départemental Vendée

La Roche-sur-Yon, , France

Site Status: RECRUITING

Centre Léon Bérard

Lyon, , France

Site Status: RECRUITING

Centre Azuréen de Cancérologie

Mougins, , France

Site Status: RECRUITING

Centre Hospitalier Universitaire de Nice

Nice, , France

Site Status: RECRUITING

Centre Antoine Lacassagne

Nice, , France

Site Status: RECRUITING

Hôpital Tenon AP-HP

Paris, , France

Site Status: RECRUITING

Centre Eugène Marquis

Rennes, , France

Site Status: RECRUITING

Groupe Hospitalier Rance Emeraude

St-Malo, , France

Site Status: RECRUITING

Countries

France

Central Contacts

Pierre-Louis SOUBEYRAN, MD, PhD

Role: CONTACT

P.Soubeyran@bordeaux.unicancer.fr

+33 5 56 33 33 37

Simone MATHOULIN-PELISSIER, MD, PhD

Role: CONTACT

s.mathoulin@bordeaux.unicancer.fr

Facility Contacts

Thomas GRELLETY, MD, PhD

Role: primary

tgrellety@ch-cotebasque.fr

+33 5 33 78 81 27

Pierre SOUBEYRAN, MD, PhD

Role: primary

p.soubeyran@bordeaux.unicancer.fr

+33 5 56 33 33 37

Romain DECOURS, MD

Role: primary

romain.decours@ght85.fr

+33 2 51 44 63 78

Chiara RUSSO, MD, PhD

Role: primary

chiara.russo@lyon.unicancer.fr

+33 4 78 78 51 95

Rémy LARGILLIER, MD, PhD

Role: primary

r.largillier@cac-mougins.fr

+33 4 92 92 37 39

Rabia BOULAHSSASS, MD

Role: primary

boulahssass.r@chu-nice.fr

+33 4 92 03 41 94

Véronique MARI, MD

Role: primary

veronique.mari@nice.unicancer.fr

+33 4 92 03 15 14

Djamel GHEBRIOU, MD, PhD

Role: primary

djamel.ghebriou@aphp.fr

Nicolas BERTRAND, MD

Role: primary

n.bertrand@rennes.unicancer.fr

+33 2 99 25 29 45

Romain DESGRIPPES, MD

Role: primary

r.desgrippes@ch-stmalo.fr

+33 2 99 21 22 64

References

Hamaker ME, Wildiers H, Ardito V, Arsandaux J, Barthod-Malat A, Davies P, Degol L, Ferrara L, Fourrier C, Kenis C, Kret M, Lalet C, Pelissier SM, O'Hanlon S, Rostoft S, Seghers N, Saillour-Glenisson F, Staines A, Schwimmer C, Thevenet V, Wallet C, Soubeyran P. Study protocol for two stepped-wedge interventional trials evaluating the effects of holistic information technology-based patient-oriented management in older multimorbid patients with cancer: The GERONTE trials. J Geriatr Oncol. 2024 May;15(4):101761. doi: 10.1016/j.jgo.2024.101761. Epub 2024 Apr 5.

Reference Type: DERIVED

PMID: 38581958 (View on PubMed)

Other Identifiers

IB2022-03

Identifier Type: -

Identifier Source: org_study_id